By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).

Key Statistics

Ownership: Public

Web Site: Ariad Pharmaceuticals, Inc.
Symbol: ARIA

Company News
AstraZeneca PLC (AZN) Rumored to be Stalking Massachusetts's Ariad Pharmaceuticals, Inc. (ARIA) 1/28/2015 12:04:43 PM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Appointment Of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, As Chief Legal And Administrative Officer 1/22/2015 11:03:18 AM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Final Decision From European Commission Endorsing Iclusig’s Approved Indications Throughout Europe 1/20/2015 11:13:36 AM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Key Strategic Objectives For 2015 Expected To Lead Company To Profitability In Three Years 1/13/2015 12:26:49 PM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Phase 2 Dose-Ranging Trial Of Iclusig (Ponatinib) To Begin By Mid-2015 1/6/2015 9:52:14 AM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Commercialization Agreement For Iclusig In Seven Central And Eastern European Countries 12/30/2014 8:07:49 AM
MA's Ariad Pharmaceuticals, Inc. (ARIA) Inks $75 Million+ Commercialization Deal In Asia 12/23/2014 6:34:00 AM
Ariad Pharmaceuticals, Inc. (ARIA) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 12/22/2014 9:52:07 AM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Follow-Up Data From Phase 1 And PACE Trials Of Ponatinib In Patients With T315I Mutation In Chronic Myeloid Leukemia 12/9/2014 1:17:29 PM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial 12/9/2014 1:12:43 PM